Evidence map›Paper›PMID 34903756›Full record

ArticleScientific reports2021

CRISPR/Cas9-mediated base-editing enables a chain reaction through sequential repair of sgRNA scaffold mutations.

Tsuyoshi Fukushima, Yosuke Tanaka, Keito Adachi, Nanami Masuyama, Akiho Tsuchiya, Shuhei Asada, Soh Ishiguro, Hideto Mori, Motoaki Seki, Nozomu Yachie and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Fracking in Tumors: A Key Drug Transport Mechanism.Annals of biomedical engineering · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tsuyoshi FukushimaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.
Yosuke TanakaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan. ytims@ims.u-tokyo.ac.jp.
Keito AdachiDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.
Nanami MasuyamaResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, 153-8904, Japan.
Akiho TsuchiyaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.
Shuhei AsadaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.
Soh IshiguroResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, 153-8904, Japan.
Hideto MoriResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, 153-8904, Japan.
Motoaki SekiResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, 153-8904, Japan.
Nozomu YachieResearch Center for Advanced Science and Technology, The University of Tokyo, Tokyo, 153-8904, Japan.
Susumu GoyamaDivision of Molecular Oncology, Graduate School of Frontier Sciences, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan. goyama@edu.k.u-tokyo.ac.jp.
Toshio KitamuraDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan. kitamura@ims.u-tokyo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell behavior is controlled by complex gene regulatory networks. Although studies have uncovered diverse roles of individual genes, it has been challenging to record or control sequential genetic events in living cells. In this study, we designed two cellular chain reaction systems that enable sequential sgRNA activation in mammalian cells using a nickase Cas9 tethering of a cytosine nucleotide deaminase (nCas9-CDA). In these systems, thymidine (T)-to-cytosine (C) substitutions in the scaffold region of the sgRNA or the TATA box-containing loxP sequence (TATAloxP) are corrected by the nCas9-CDA, leading to activation of the next sgRNA. These reactions can occur multiple times, resulting in cellular chain reactions. As a proof of concept, we established a chain reaction by repairing sgRNA scaffold mutations in 293 T cells. Importantly, the results obtained in yeast or in vitro did not match those obtained in mammalian cells, suggesting that in vivo chain reactions need to be optimized in appropriate cellular contexts. Our system may lay the foundation for building cellular chain reaction systems that have a broad utility in the future biomedical research.

Indexed as

CRISPR-Cas SystemsDNA RepairGene EditingMutationCytosine DeaminaseHEK293 CellsHumansRNA, Guide, CRISPR-Cas SystemsTATA BoxThymidineCytosine DeaminaseRNA, Guide, CRISPR-Cas SystemsThymidine

Identifiers

PMID34903756
PMCPMC8668876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.